NEW YORK (GenomeWeb) – Saying a recent uptick in Bruker's share price represents a less favorable risk/reward profile, investment bank ISI Group today downgraded the company's stock to a Neutral rating.

Analyst Ross Muken lowered Bruker from a previous Buy rating but raised the price target on the firm's shares to $25.50 from $24.50.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

 Senator Lamar Alexander (R-Tenn.), who chairs the Senate health committee, will be retiring at the end of his term, Stat News reports.

UCSF researchers find that having two X chromosomes may contribute to women's longer lifespans, according to Discover's D-brief blog.

The Wall Street Journal reports on the US Centers for Disease Control and Prevention's use of genetic approaches to study foodborne illnesses.

In PNAS this week: immune cell profiling of wild baboons by social status, metabolomics profiling of esophageal tumors, and more.